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2007n distinction to anatomical and physiological
maging, molecular imaging aims to illuminate
iological processes in vivo via sophisticated
maging agents targeted to key molecules and
ells. As most disease processes have a biolog-
cal basis, molecular imaging offers the follow-
ng abilities: 1) to study precisely the role of
mportant molecules and cells in a disease
rocess in vivo, in serial fashion; 2) to evaluate
he biological effects of molecular and cellular
herapeutics; and 3) to refine risk prediction
nd risk stratification by incorporating biolog-
cal information into traditional clinical assess-
ents. Given the inability to routinely obtain
issue for biological analyses in many cardio-
ascular disease (CVD) conditions, molecular
maging approaches are anticipated to play an
mportant role in CVD assessment.
In this inaugural review of the year in mo-
ecular imaging, we present important contri-
utions chronologically, focusing on 4 areas: 1)
therosclerosis, 2) myocardial infarction, 3)
tem cell therapy, and 4) multimodality imag-
ng and theranostics. We close with an update
n the clinical translation of this technology to
VD patients.
ovel Imaging Probes and Biological
pplications
n the past several years, advances in molecular
maging agent and hardware technology have
rom the *Department of Medicine, Beth Israel Deaconess Medic
ardiology Division, and Center for Molecular Imaging Research
chool, Boston, Massachusetts. Dr. Jaffer is a consultant for VisE
oward Hughes Medical Institute Early Career Award, American
he Donald W. Reynolds Foundation. Review period: October 1,anuscript received October 6, 2008; revised manuscript received Octnabled rapid growth of experimental CVD
nvestigations. An array of imaging probes are
vailable for cardinal biological processes, in-
luding inflammation, angiogenesis, apoptosis,
xidative stress, calcification, cellular traffick-
ng, and reporter gene expression. In addition,
maging agents now provide readouts for many
linical CVD imaging modalities including
ardiac magnetic resonance (CMR), positron
mission tomography (PET), single-photon
mission computed tomography (SPECT), op-
ical, ultrasound, and computed tomography
CT) imaging. The following sections high-
ight novel and substantive advances in the past
ear of preclinical molecular imaging studies of
VD. A number of promising agents/
pproaches are expected to translate into the
linical arena.
therosclerosis
therosclerosis is a chronic inflammatory and
ipid deposition disorder (1). Early atheromata
evelop in areas of activated endothelium that
ttract and bind circulating monocytes. Resi-
ent monocytes then differentiate into plaque
acrophages that scavenge oxidized phospho-
ipids and evolve into foam cells. Macrophages
ecrete proinflammatory mediators that may
eaken the fibrous cap. Over time, apoptosis of
acrophages promotes formation of a necrotic
ore and subsequent plaque expansion. Ulti-
ately, this environment may promote fibrous
enter, and the †Cardiovascular Research Center,
assachusetts General Hospital, Harvard Medical
edical and has received financial support from
rt Association Scientist Development Grant, and
, to September 30, 2008.ober 28, 2008, accepted November 6, 2008.
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98ap disruption on consequent thrombosis leading to
yocardial infarction, stroke, and ischemic limbs.
Molecular imaging can visualize the critical bio-
ogical aspects that are otherwise undetected by
onventional imaging methods. In addition to un-
aveling the molecular and cellular biology of
therogenesis in vivo, this approach may better
dentify high-risk plaques and patients and could
ffer refined risk stratification. In addition, as most
therosclerosis therapeutics possess a biological
echanism of action, molecular imaging offers a
ew approach to assess biological efficacy of athero-
clerosis therapies.
onocyte chemotactic protein (MCP)-1 detec-
ion with noninvasive radionuclide imaging. The
acrophage MCP-1 peptide is up-regulated in
theromata and mediates monocyte recruitment to
he vessel wall via its cognate chemokine (C-C
otif) receptor 2 (CCR2). Hartung et al. (2)
mployed technetium Tc 99m-labeled recombinant
CP-1 (99mTc-MCP-1) to noninvasively detect
CR2-expressing monocyte/macrophages in ath-
rosclerotic plaques of rabbits (2). The 99mTc-
CP-1 signal localized to atheromata on in vivo
PECT imaging and resected vessels demonstrated
-fold greater radioactivity (0.06% injected dose per
ram tissue [%ID/g]) than injected control rabbits
n a normal chow diet. Immunoreactive macro-
hages correlated with mean 99mTc-MCP-1 uptake
n aortic lesions (R2  0.76).
OMMENT. Radiolabeled 99mTc-MCP-1 expands
he imaging armamentarium for noninvasive visu-
lization of plaque macrophages. Additional gains
re anticipated with integrated nuclear/CT imaging
nd analogous PET tracers offering higher spatial
esolution. Mechanistic studies may clarify the rel-
tive binding of radiolabeled MCP-1 to trafficking
onocytes versus resident monocytes/macrophages
n atheroma.
ultichannel NIRF imaging of atheroma in-
ammation and osteogenic activity. To explore
he temporospatial relationship between in vivo
steogenesis (bone formation, plaque calcification)
nd plaque inflammation, Aikawa et al. (3) performed
erial intravital confocal fluorescence microscopy of
urine carotid plaques following coinjection of an
steogenic sensitive probe (near-infrared fluoro-
hrome conjugated to a bisphosphonate) and a
acrophage-avid near-infrared fluorescence
NIRF) iron oxide nanoparticle. Serial molecular
maging provided the first in vivo evidence that
acrophage infiltration and plaque inflammation
receded osteogenesis (Fig. 1). Intriguingly, NIRF asteogenic activity was visualized in plaques without
istological or CT evidence of calcification. Statin
reatment decreased macrophage content and
steoblast-like activity, extending the association
etween inflammation and osteogenesis. Ex vivo
uorescence imaging of human carotid endarterec-
omy specimens demonstrated avid uptake of the
IRF nanoparticle and bisphosphonate agents that
olocalized with immunoreactive macrophages and
steopontin, respectively.
OMMENT. Atherosclerotic calcification predicts
uture cardiovascular events, and superficial calcified
odules delineate a high-risk plaque subtype (4).
maging of inflammation and osteogenesis via
ranslatable NIRF imaging systems (e.g., intravas-
ular catheters or tomographic systems) could help
lucidate the role of lesional calcification in plaque
upture.
PECT imaging of caspase inhibitor effects on
laque apoptosis. Dying cells may hasten plaque
upture by weakening of the protective fibrous cap
nd propagation of the underlying necrotic core (4).
o image the effects of caspase inhibitors on plaque
poptosis in vivo, Sarai et al. (5) used 99mTc-labeled
uman recombinant annexin A5, a native protein
hat binds avidly to phosphatidylserine residues
xposed on apoptotic cells. Rabbits with aortic
therosclerosis received a nonselective caspase in-
ibitor; or a specific inhibitor of caspase-1, -3, -8,
r -9; or no inhibitor. Six hours after drug admin-
stration, 99mTc-labeled human recombinant or
utant annexin A5 was infused followed by micro-
PECT/CT imaging at 1 h. Compared with nor-
al rabbits, radiolabeled annexin A5 signal was
0-fold greater in aortas of rabbits with atheroscle-
osis (0.05% ID/g). Annexin A5 apoptosis SPECT
ignal was markedly and modestly decreased by
road and specific caspase inhibition, respectively.
istology revealed reduced macrophage apoptotic
gures (terminal deoxyribonucleotide transferase
dT-mediated nick-end labeling positive) after broad
aspase, caspase-1, and caspase-3 inhibitor treatment.
OMMENT. Broad and specific caspase inhibitors
uppressed atherosclerotic plaque apoptosis in vivo.
iven the clinical potential of annexin A5 in apoptosis
laque imaging (6), this approach may offer a new
ethod to assess antiapoptotic therapies.
PECT/CT imaging of monocyte trafficking to
theroma at baseline and following short-term
tatin therapy. Kircher et al. (7) developed a
oninvasive 3-dimensional imaging, tracking,
nd quantification strategy to assess in vivo
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99onocyte recruitment, a critical process in
therogenesis. Adoptively transferred monocytes
abeled with the FDA-approved nuclear agent
ndium In 111 (111In) oxyquinolone were injected
nto apolipoprotein E deficient (ApoE/) mice
ith atherosclerosis. Mice next underwent serial
ntegrated micro-SPECT/CT imaging from 30
in to 10 days. The SPECT/CT images revealed
racer localization to ascending aortic plaques
y 5 days that was confirmed by ex vivo auto-
adiography and histology. Intriguingly, short-
erm statin therapy reduced plaque monocyte
ontent by 5-fold, without altering plasma
holesterol.
OMMENT. This study offers a new in vivo ap-
roach to quantitatively study the role of monocytes
n atherogenesis, and potentially in patients. In
ddition, the short-term statin results demonstrate
ow molecular imaging can connect biological in-
ights and relevant clinical studies such as the
Figure 1. In Vivo Multichannel NIRF Imaging of Plaque Macroph
(A) Calciﬁed carotid artery atherosclerotic plaque gross morphology
phages (green) and calciﬁcation (red). Merged intravital microscopy
tion (bar  500 m). (B) Cross-sectional ﬂuorescence microscopy w
 200 m). Reprinted, with permission, from Aikawa et al. (3). ApoIRACL (Effects of Atorvastatin on Early Recur- Cent Ischemic Events in Acute Coronary Syn-
romes) trial (8).
ual-targeted microparticle CMR of activated
ndothelial adhesion molecules. To image acti-
ated endothelium, a identifier of high-risk plaques
4), McAteer et al. (9) conjugated CMR-detectable
.5-m diameter microparticles of iron oxide
MPIO) to vascular cell adhesion molecule
VCAM)-1 and to P-selectin antibodies. After
onfirmation of VCAM-1-MPIO binding to
ouse endothelium in vitro, mice received an
ntravenous or left ventricular injection of either
PIO conjugated to VCAM-1 or P-selectin
lone, or in combination (dual-targeted MPIO).
ompared with single-labeled particles, dual-
abeling markedly increased MPIO binding to
ndothelium at sites overlying atheroma forma-
ion on ex vivo CMR, but not at areas without
etectable atherosclerosis.
OMMENT. The dual-targeted MPIO extends the
s and Osteogenesis in Aged ApoE/ Mice
related with intravital ﬂuorescence microscopy images of macro-
ages reveal no colocalization between macrophages and calciﬁca-
mage overlay revealed a similar spatially distinct relationship (bar
 apolipoprotein deﬁcient; NIRF  near-infrared ﬂuorescence.age
cor
im
ith i
/MR library of activated endothelium targeted
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100gents (10,11). Further studies will determine the
bility of MPIO to provide in vivo MR images of
ctivated endothelium of atheromata.
n vivo CMR evaluation of p38 MAPK inhibi-
ion on plaque inflammation. Magnetic resonance
mages enhanced with macrophage-targeted magnetic
anoparticle of ultrasmall particle of superparamag-
etic iron oxide (USPIO) were employed to evaluate
nti-inflammatory properties of SB-239063, a novel
38 mitogen-activated protein kinase (MAPK) inhib-
tor, on murine atherosclerosis (12). Following 21-day
nfusions of angiotensin II to activate p38 MAPK and
lternate inflammatory pathways that promote leuko-
yte recruitment, T2-weighted 9.4-T CMR demon-
trated high plaque signal loss indicating USPIO
agnetic nanoparticle (MNP) deposition into
laques. In contrast, minimal plaque signal loss was
vident in angiotensin II-treated ApoE/ mice re-
eiving the p38 MAPK inhibitor. Intriguingly, ex vivo
MR and histopathological analysis revealed minimal
ifferences in plaque volume and macrophage content
etween SB-239063 and control animals, suggesting
hat p38 MAPK inhibition decreased macrophage
ptake of MNP.
OMMENT. This study demonstrates the capability
f molecular CMR to evaluate anti-inflammatory
ffects of novel atherosclerosis therapeutics and
uggests that p38 MAPK inhibition may attenuate
acrophage phagocytic activity.
olecular CMR of MMP expression. Inflamma-
ory proteases may degrade extracellular matrix
rotein and promote plaque rupture (1). Lancelot et
l. (13) developed a new molecular imaging agent
P947) for CMR detection of matrix metallopro-
einase (MMP) expression in vivo. The P947 agent
s a gadolinium chelate attached to a MMP peptide
nhibitor that blocks MMP-1, -2, -3, -8, -9, and
13 activity in vitro. In a detailed human carotid
ndarterectomy substudy, P947 enhanced MMP-
ich complex internal carotid atheromata 2-fold
ore than MMP-poor external and common ca-
otid segments. In vivo, ApoE/ mice receiving
947 (100 mol Gd/kg) showed significantly
reater and more durable CMR signal enhance-
ent than the control gadolinium-tetraazacy-
lododecanetetraacetic acid (DOTA) group. The
947 enhancement concentrated at the fibrous cap
nd plaque shoulders and was notably absent from
ipid cores.
OMMENT. The P947 agent offers a high-
esolution noninvasive approach to detect plaque
ulti-MMP expression by CMR and complements she ability to noninvasively image MMP activity in
ivo using NIRF imaging (14).
laque inflammation and thrombosis detection
y combined 18FDG-PET/CT imaging. Com-
uted tomographic angiography and fluorodeoxygen-
se F 18 (18FDG)-PET were employed to identify
rterial thrombi overlying inflamed aortic atheroscle-
otic plaques in rabbits (15). Before imaging, thrombi
ere triggered by administration of intraperitoneal
ussell’s viper venom and intravenous histamine.
omputed tomographic angiography detected
hrombi with 92% sensitivity and 89% specificity. Aziz
t al. (15) found that rabbits subjected to thrombosis
riggering had greater 18FDG accumulation than did
ntriggered animals, although changes were not sig-
ificant among different triggered animals with and
ithout thrombosis. On histology, macrophage den-
ity was highest in 18FDG-avid atheroma that devel-
ped thrombosis.
OMMENT. High 18FDG signal may identify
hrombus-containing plaques. It is plausible that
ecruited leukocytes after thrombus triggering also
ontribute to the overall 18FDG signal.
isualizing oxidized phospholipids via noninva-
ive CMR. Oxidized phospholipids promote mac-
ophage MMP release and apoptosis and conse-
uent plaque instability (1). Briley-Saebo et al. (16)
robed oxidized phospholipid constituents in ath-
roma of ApoE/ mice using gadolinium-infused
icelles (20 nm) covalently bound to monoclonal
ntibodies (MDA2, IK17, or E06) that recognize
xidation-specific epitopes of lipoproteins. In vivo
.4-T CMR showed maximal aortic wall uptake of
argeted micelles (125% to 231% over control mi-
elles) between 72 and 96 h (Fig. 2). Competition
xperiments pre-injecting unlabeled MDA2 anti-
ody diminished the observed CMR signal en-
ancement, attesting to the in vivo specificity of the
DA2 imaging agent. Ex vivo experiments and
onfocal fluorescence microscopy revealed a close
ssociation of oxidation-specific antibody micelle
robes with tissue macrophages in atheromata.
OMMENT. Noninvasive CMR of oxidized lipids
sing targeted micelles offers a new opportunity to
tudy oxidative stress in vivo and to identify high-
isk plaque subtypes.
MR detection of activated platelet glycoprotein
Ib/IIIa for thrombosis detection and monitor-
ng of fibrinolysis. Magnetic resonance imaging
as used to noninvasively monitor thrombus for-
ation and thrombolysis in mice (17). Nonocclu-ive carotid thrombi were formed with 6% ferric
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101hloride (15% to 40% occlusive). Activated platelet
argeted MPIO (sized 1 m) were linked to a
ingle-chain antibody specific for ligand-induced
inding sites (LIBS) on conformationally active
lycoprotein IIb/IIIa. Continuous CMR scans re-
ealed progressive thrombus signal loss in mice
njected with LIBS-MPIO but not in control
PIO mice. Successful thrombolysis of subocclu-
ive thrombi with human or mouse urokinase di-
inished the LIBS-MPIO CMR signal loss and
ignificantly reduced thrombus extent on histolog-
cal examination. Histology confirmed the incorpo-
ation of LIBS-MPIO at platelet-rich areas at the
hrombus surface. The total MPIO content corre-
ated with overall thrombus size and with the
agnitude of CMR signal void. In addition, ex vivo
Figure 2. CMR of Oxidized Phospholipids in Atherosclerosis
Serial MR molecular imaging of a representative abdominal aorta (a
micelles targeted to oxidized phospholipids (MDA2, IK17, EO6), grea
when compared with control (untargeted, IgG) micelles. Competitio
signal increase. The inferior vena cava can be identiﬁed to the left
(16). CMR  cardiac magnetic resonance; IgG  immunoglobulin GMR studies of carotid endarterectomy specimens nrom 2 patients with symptomatic carotid disease
lso showed LIBS-MPIO–specific binding at the
pecimen surface that was confirmed on histological
xamination.
OMMENT. The LIBS-MPIO– enhanced CMR
ffers a new strategy to diagnose nonoccuslive
hrombi with activated platelets and to monitor
hrombolysis in vivo. The utility of this approach
or fully occlusive thrombi remains to be deter-
ined. With the potential development of biode-
radable MPIOs, clinical CMR of microthrombi
n carotid atheromata may enable improved risk
tratification.
ositive-contrast CMR to detect plaque mac-
ophages. Detection of plaque-localized MNP sig-
s) in ApoE/ mice. After injection of 0.075 mmol Gd/kg
and more durable aortic plaque signal enhancement was seen
periments with unlabeled targeted antibodies limited the CMR
e aorta. Reproduced, with permission, from Briley-Saebo et al.
er abbreviations as in Figure 1.rrow
ter
n ex
of thal loss may be challenging due to limited spatial
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102esolution, low baseline signal-to-noise ratio, and
usceptibility artifacts from surrounding tissues
e.g., lungs). To enable positive-contrast MNP/
SPIO detection, a new CMR sequence termed
nversion recovery with ON-resonant water sup-
ression (IRON) was evaluated in atherosclerotic
abbits (18). The IRON sequence uses a spectrally
elective pre-pulse saturation signal to suppress
n-resonant protons without saturating off-
esonant protons induced by MNP-derived local
eld gradients. In 7 rabbits with atherosclerosis and
controls, MNP (MION-47 clinical-type USPIO, 500
mol/kg) was administered followed by serial 3-T
RON-CMR at 1, 3, and 6 days. In atherosclerotic
abbits only, progressive aortic wall enhancement
ccurred at confirmed sites of atheroma. The
RON-CMR provided superior MNP contrast en-
ancement and detection when compared with
raditional black blood approaches. Positive CMR
ontrast correlated with plaque macrophages and
rovided excellent operating characteristics (area
nder the curve: 0.92, sensitivity: 91%, specificity:
9%) for detecting macrophage-rich plaques.
OMMENT. The development of a positive-
ontrast clinical MNP imaging method is an im-
ortant step toward improving the sensitivity to
etect macrophage infiltration, which is a marker of
igh-risk atherosclerotic plaques. Alternative
romising positive-contrast CMR reporters include
new gadolinium-containing immunomicelle tar-
eting the macrophage scavenger receptors (19).
yocardial Infarction
he sequelae of myocardial infarction (MI) are
umerous and devastating. In the acute phase,
yocardial ischemia compromises cardiac function
nd local inflammation at the infarct site may
otentiate ventricular rupture. As the acute inflam-
atory phase resolves, infarcted myocardium is
eplaced by fibrotic scarring that predisposes to fatal
rrhythmias and initiates a cascade of maladaptive
eurohormonal and structural changes that pro-
otes the development of congestive heart failure.
olecular imaging is positioned to shed light on
any of these delicately balanced and highly coor-
inated biological processes. In particular, open
uestions remain about whether the inflammatory
nd angiogenic repair processes can be perturbed to
avorably influence myocardial healing. It is envi-
ioned that relevant molecular imaging readouts
lso might provide a biological basis for selecting
pecific combinations of therapeutic agents follow- cng MI, such as angiotensin-converting enzyme
nhibitors, beta-blockers, angiotensin II receptor
lockers, aldosterone receptor antagonists, and
ovel therapeutics.
PECT/CT imaging of factor XIII activity and
odulating therapies following acute MI. Factor
III (FXIII) is a thrombin-activated transglutami-
ase that promotes infarct healing. Nahrendorf et
l. (20) studied the role of FXIII in post-MI human
ubjects and then in vivo using SPECT molecular
maging of FXIII in mouse infarcts. In 9 patients
hat died of post-MI cardiac rupture, diminished
yocardial FXIII protein was found compared with
he amount of myocardial FXIII in 9 control hearts.
n vivo, mice were subjected to infarction followed
y SPECT/CT imaging with 111In-DOTA-FXIII,
radiolabeled activated FXIII peptide substrate.
igh SPECT signal was noted in the infarct zone.
omputed tomographic delayed-enhancement
MR further colocalized the focal SPECT signal
o the anterolateral infarct and increased FXIII
ctivity correlated with leukocytes, collagen deposi-
ion, and angiogenesis. Following dalteparin (a low
olecular weight heparin antithrombin agent) ther-
py, SPECT images revealed diminished FXIII
nfarct activity that was associated with increased
ortality (64% by day 7 after MI vs. 10% in control
nimals) secondary to myocardial rupture. Remark-
bly, administration of supplemental FXIII in-
reased FXIII SPECT signal, eliminated mortality
0% at 7 days), and improved the left ventricular
LV) ejection fraction on day 21 by 20%.
OMMENT. Noninvasive molecular imaging of
XIII may provide valuable insights into the integ-
ity of the healing infarct and propensity to rupture.
upplementing with FXIII appears beneficial, and
XIII suppression by the antithrombin dalteparin
ppears detrimental, although potential clinical
rothrombotic effects of these therapies remain
nknown.
MR of MPO activity and statin effects after
I. Myeloperoxidase (MPO) is a proinflamma-
ory reactive oxygen species that may adversely
ffect infarct healing. Myeloperoxidase activity was
valuated in a murine MI model using an activat-
ble gadolinium reporter that oligomerizes and
nhances CMR signal in peroxidase-rich environ-
ents (21). In mice 2 days after surgical ligation of
he left coronary artery, MPO-gadolinium (0.3
mol/kg, 7-T CMR) preferentially and more du-
ably localized to the infarct zone compared with
nlabeled gadolinium. Repeat MPO-gadolinium
ontrast administration on day 5 showed reduced
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103nfarct MPO activity (Fig. 3). In vivo imaging
ndings correlated well with infarct MPO activity.
n an ischemia-reperfusion injury model, statin
re-treatment significantly decreased MPO activity
n vivo at 24 h.
OMMENT. Magnetic resonance imaging of MPO
ctivity is a new approach to image oxidative stress
n vivo and permits an integrated noninvasive mo-
ecular and functional assessment of MI.
ET/CT imaging of VEGF receptor expression
fter MI. Vascular endothelial growth factor
VEGF) receptor expression on neoangiogenic ves-
els is up-regulated after MI. To noninvasively
mage VEGF receptors, Rodriguez-Porcel et al.
22) employed the PET tracer copper Cu 64
64Cu)-DOTA-VEGF121. Following left coronary
rtery ligation in rats, PET/CT imaging revealed
bundant 64Cu-DOTA-VEGF121 uptake in infarct
ones that peaked at day 3 after MI (0.97% ID/g)
nd was significantly greater than baseline myocar-
ial uptake, sham controls, or infarcted animals
eceiving the control agent 64Cu-DOTA-
EGFmutant. The
64Cu-DOTA-VEGF121 signal
rogressively declined over 2 weeks to baseline.
utoradiography and immunofluorescence VEGF
eceptor studies confirmed the in vivo imaging
ndings.
OMMENT. Noninvasive imaging of myocardial
Figure 3. Temporal Molecular CMR of MPO Activity in a Mouse
Representative MR short-axis slices on days (A) 2 and (B) 8 after co
tions. The signiﬁcant MPO-gadolinium enhancement detected on d
diminished greatly by day 8. (C) In vivo MPO infarct activity peaked
animals demonstrated a similar MPO tissue activity time course. (E)
to 4 after MI that lessened by day 8. The MPO protein was minimal
with guaiacol-derived MPO tissue activity. Reproduced, with permiss
glyceraldehyde-3-phosphate dehydrogenase; MI  myocardial infarEGF receptor expression after MI may shed purther insight into neoangiogenic changes that
ccur after myocardial damage. Shorter half-life
ET tracers (e.g., fluorine F 18 or gallium Ga 68)
ould facilitate clinical imaging of VEGF receptors.
luorescence and SPECT imaging of angioten-
in receptors following MI. Angiotensin (AT)-II
eceptor expression was assessed in a mouse model
f ischemic heart failure using in vivo epifluores-
ence microscopy and noninvasive SPECT/CT im-
ging (23). Two AT-targeted agents were devel-
ped: a fluorescein-derivatized angiotensin peptide
nalog (picomolar affinity for AT type I and II
eceptors) for optical imaging, and 99mTc-labeled
osartan, a clinical AT type I receptor blocker, for
PECT imaging. Following left coronary artery
igation, AT-targeted optical or SPECT tracers
ere injected at various time points from immedi-
tely after MI up to 12 weeks after MI. On
eal-time intravital epifluorescence microscopy of
pen-chested beating hearts, angiotensin peptide
nalog localized selectively to the infarcted region
ith minimal uptake in remote regions. Infarct
uorescence progressively increased from 1 to 3
eeks and then declined from 6 to 12 weeks, but
ngiotensin peptide analog colocalized primarily
ith myofibroblasts rather than cardiomyocytes or
ndothelial cells. On noninvasive SPECT/CT im-
ging, at 3 weeks, 99mTc-losartan enhanced in-
arcted regions with a 2.4-fold greater uptake com-
odel
ry artery ligation. Dotted lines identify the short-axis view loca-
after MI in the akinetic infarcted left ventricular free wall (arrows)
day 2 after MI. (D) Guaiacol MPO assay of infarcts from the same
stern blots conﬁrmed signiﬁcant infarct MPO expression on days 1
earts of sham-operated mice. (F) Infarct MPO activity correlated
from Nahrendorf et al. (21). CNR  contrast-to-noise ratio; GAPDH 
; MPO  myeloperoxidase; other abbreviations as in Figure 2.MI M
rona
ay 2
by
We
in h
ion,ared to noninfarcted regions of control hearts.
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104OMMENT. Ventricular remodeling after MI is in
art mediated by up-regulation of the renin-
ngiotensin system and myocardial AT-II receptor
xpression. Molecular imaging of myocardial AT-II
eceptor expression may predict the evolution of
eart failure and help guide AT-II receptor blocker
herapy, duration, and intensity.
ltrasound imaging of inflammation during
ost-ischemic angiogenesis. Molecular imaging
f inflammation in vascular development was as-
essed using contrast-enhanced ultrasound with
-m diameter microbubbles targeted to comple-
ent receptors on activated neutrophils, the alpha5-
ntegrin of the fibronectin receptor on monocytes,
r VCAM-1 on endothelium (24). Unlabeled mi-
robubbles were employed for tissue perfusion im-
ging. Two in vivo models were employed: 1)
ubcutaneous Matrigel (BD Biosciences, San Jose,
alifornia) implants to facilitate de novo vasculo-
enesis; and 2) hind-limb ischemic arteriogenesis
ollowing ligation of the distal common iliac artery.
n the middle of Matrigel implants, increased
lpha5-integrin and VCAM-1 ultrasound signals
emporally preceded increased perfusion signals,
uggesting that inflammation occurred before the
evelopment of functional angiogenic vasculature.
n hind-limb ischemia, targeted molecular imaging
evealed that neutrophils, monocytes, and VCAM-1
xpression preceded increased perfusion to the limb.
ice lacking the monocyte chemoattractant protein
CP-1 exhibited diminished monocyte signals
hen compared with wild-type mice as expected,
owever perfusion was not significantly reduced,
resumably due to the early day 4 imaging time
oint.
OMMENT. Behm et al. (24) demonstrate the abil-
ty to monitor inflammatory biomarkers noninva-
ively during vascular development and remodeling
n response to tissue ischemia. Detection of im-
aired inflammatory responses may guide earlier
nitiation of pro-angiogenic therapies engineered to
alvage ischemic tissue.
MR of collagen deposition in post-MI scar-
ing. Helm et al. (25) investigated a new multiva-
ent gadolinium-based collagen probe (EP-3533, 3
adolinium ions per type I collagen binding pep-
ide) in cardiac ischemia-reperfusion injury. The
P-3533 probe binds collagen reversibly with mi-
romolar affinity. Multivalency enables very high
1 relaxivity for EP-3533, 5-fold that of untar-
eted gadolinium. Serial 4.7-T CMR scans at day 1
nd day 42 post-MI after EP-3533 or gadolinium
njection were performed. Compared with gadolin- tum, EP-3533 provided greater and more durable
195 vs. 25 min for gadolinium) infarct enhance-
ent. The circumferential extent of fibrosis de-
ected by EP-3533 enhancement correlated well
ith picrosirius red-detected collagen (R2  0.97)
Fig. 4). Inductively coupled plasma mass spec-
rometry confirmed higher gadolinium concentra-
ion in scarred versus normal myocardium.
OMMENT. Collagen molecular CMR detects
ost-infarction scarring with improved conspicuity
han conventional delayed gadolinium enhance-
ent does and may have broad applications for
argeted fibrosis imaging.
onitoring inflammation after ischemia with
erfluorocarbon-enhanced fluorine CMR.
anoemulsions of biochemically inert perfluorocar-
ons (PFCs, specifically perfluoro-15-crown-5-
ther) were investigated for detecting cellular in-
ammation in mouse models of acute cardiac (left
nterior descending artery [LAD] ligation) and
erebral (photothrombosis) ischemia (26). Follow-
ng PFC injection, fluorine F 19 (19F) CMR of
ensity centrifugated blood samples revealed that
ononuclear cell uptake of PFCs peaked by day 2
ut was absent on day 3. Therefore, PFCs were
njected 2 h after the initial MI and then reinjected
t day 4. Multinuclear (proton and fluorine) CMR
as performed serially at days 1, 3, and 6 after MI.
ocal fluorine signal was progressively detected in
he infarct only, as confirmed by anatomical CMR
Fig. 5). Fluorescent PFCs localized to the infarc-
ion border zone, but not noninfarcted nor necrotic
reas. Flow cytometry revealed that 80% of PFCs
olocalized with mononuclear cells. The CMR
ensitivity detection threshold of this approach was
stimated to be as few as 400 PFC-labeled cells.
OMMENT. This novel study by Flogel et al. (26)
emonstrates a positive-contrast CMR approach to
etect cellular inflammation after MI. Two advan-
ages of this approach include: 1) the lack of 19F
ackground in the body, enhancing signal-to-noise
atio, and 2) multinuclear proton imaging capability
or concomitant cardiac anatomy, function, and scar
maging. Clinical fluorine CMR with PFCs such as
erflubron, an artificial blood substitute, appears
easible.
ngiogenesis detection in hibernating myocar-
ium. A swine model of hibernating myocar-
ium was created using an Ameroid constrictor
Research Instruments NW, Lebanon, Oregon)
laced around the left circumflex artery. After 2
o 3 weeks, swine underwent electroanatomic
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105apping-guided intramyocardial injection of ei-
her VEGF to stimulate therapeutic angiogenesis
r saline control. Two weeks later, animals re-
eived an injection of Iodine I 123 (123I)-Gluco-
rginine-Glycine-Aspartate peptide motif
RGD), a glycosylated cyclic peptide SPECT
maging agent that binds integrin alphaV-beta3, a
ransmembrane glycoprotein up-regulated on the
Figure 4. Molecular CMR of Collagen Presence in MI
(A, B, D, E) Mid-ventricular short-axis MR images at 2 levels and (C,
stained with picrosirius red were compared following mouse coron
using a double inversion recovery gradient echo sequence of ische
administration that matched closely with (C, F) picrosirius red stain
tions of myocardial scarring. Reproduced, with permission, from He
Figure 5. In Vivo Molecular Imaging of Macrophage Inﬁltration
(A) Corresponding 1H and 19F MR images 4 days after mouse left a
zone (I) and near the surgical thoracotomy site (T). Perﬂuorocarbon
and 19F (pseudocolor) images show that PFC-labeled macrophages
note, an additional PFC bolus was delivered on day 4 to compensa
with permission, from Flogel et al. (26). OP  operative procedure;
other abbreviations as in Figure 2.ndothelial cells of neoangiogenic vessels (27).
he 123I-Gluco-RGD SPECT imaging at 6
eeks in VEGF-injected swine revealed en-
ancement in the Ameroid constrictor territory
hat correlated with 15% greater perfusion and
light improvement in global and regional LV
unction. Comparatively, controls showed mini-
al 123I-Gluco-RGD enhancement, diminished
issue sections of corresponding locations in the left ventricular
rtery ischemia-reperfusion. (A, D) Anatomic images obtained
regions showed (B, E) areas of enhancement 40 min after EP-3533
patterns on histology (9 magniﬁcation). Arrows identify loca-
t al. (25). Abbreviations as in Figures 1 and 2.
Infarcted Hearts Using PFC-Enhanced 19F CMR
ior descending ligation reveals 19F signal uptake within the infarct
ere initially injected 2 h after infarction. (B) Fusion 1H (grayscale)
umulate over time in the infarct and surgical injury zones. Of
r PFC particle clearance by 3 days after injection. Reproduced,
 perﬂuorocarbon; 1H  hydrogen H 1; 19F  ﬂuorine F 19;F) t
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106yocardial blood flow, and progressive LV dys-
unction. Injection of VEGF was associated with
educed fibrosis and higher capillary density on
istology. Lectin staining correlated well (R2 
.8) with 123I-Gluco-RGD uptake.
OMMENT. Iodine I 123-Gluco-RGD SPECT
maging offers a noninvasive method to assess
ngiogenic-modulating therapies in ischemic issues.
linical infarct angiogenesis imaging has been re-
ently performed using the PET sister agent 18F-
alakto-RGD described in the Clinical Investiga-
ions section (28).
temCell Therapy
tem cell therapy holds great promise for the
reatment of cardiovascular disease. Of particular
nterest is stem cell therapy in MI, which has the
otential to reduce or even improve myocardial
unction not only through myocardial regeneration
ut also enhancement of neovascularization within
he infarct zone to restore myocardial perfusion.
hough clinical studies of stem cell therapy remain
reliminarily encouraging, future trials incorporat-
ng molecular imaging may offer much greater
nsight into the critical processes of stem cell
ngraftment, survival, differentiation, and migra-
ion. In practice, current methods require labeling
n ex vivo population of stem cells with an imaging
gent or using stem cells with genetically encoded
maging reporters. Future screening efforts may
dentify injectable agents with specific targeting
apabilities to particular stem cells.
erial optical tracking of embryonic stem cell-
erived endothelial cell therapy after MI. Regen-
rative stem cell therapy may offer the ability to
estore viable myocytes that limit or reverse LV
ysfunction. To quantitatively track the in vivo
urvival and effects of embryonic stem cell-derived
ndothelial cells (ESC-EC), Li et al. (29) im-
lanted ESC-EC into murine hearts following
xperimentally induced MI. Murine ES cells were
endered optically detectable following viral trans-
ection with ubiquitin promoter driving firefly lu-
iferase and monomeric red fluorescence protein for
ioluminescence and fluorescence detection, re-
pectively. Transfected ESC were differentiated
nto EC. Ten minutes after left coronary ligation,
SC-EC were injected directly into the heart at the
eri-infact zone and noninvasively imaged sequen-
ially over 8 weeks. After day 1, there was signifi-
ant progressive diminution of signal, correspond-
ng to decreased cell survival from 12% to 1% over peeks 1 to 8 (Fig. 6). Compared with control
hosphate-buffered saline injection, ESC-EC in-
ection improved LV function at 8 weeks, and
istological analysis demonstrated greater peri-
nfarct neoangiogenesis. Interestingly, greater neo-
ascularization occurred despite the poor overall
urvival of ESC-EC. No evidence of myocardial
egeneration was evident. Compared with differen-
iated ES cells, undifferentiated ES cell injection
nduced teratoma formation associated with de-
reased survival.
OMMENT. Molecular imaging strategies can track
he fate and function of cardiac stem cell transplants
n vivo. Clinical translation of this approach for
ssessing human stem cell transplants may be fea-
ible via PET gene expression reporters such as
erpes simplex virus type 1 thymidine kinase (30).
racking intracoronary progenitor cell delivery
fter MI with PET/CT. The temporal dynamics
nd efficiency of intracoronary-injected 18FDG-
abeled circulating progenitor cell (CPC) myocar-
ial engraftment was assessed in vivo by combined
ET/CT imaging in a porcine MI model (31).
nfarction was induced by catheter-based balloon
cclusion of the mid left circumflex coronary artery
or 90 min. Infarct size and cardiac function were
valuated by CMR at 48 h post-infarction, after
hich freshly harvested human and porcine CPC
adiolabeled ex vivo with 18FDG (98% viability)
ere administered via an intracoronary catheter
ithin the left circumflex artery according to 2
elivery strategies: 1) 3 cycles of balloon occlusion
ollowed by an equal duration of reperfusion (1 
07 cells per injection); or 2) a high-concentration
ingle-bolus injection (3  107 cells) without bal-
oon occlusion. In the low-dose balloon occlusion
roup, dynamic 3-dimensional PET/CT revealed a
epetitive cyclical rise in 18FDG-CPC myocardial
ignal during each balloon occlusion, followed by
ubsequent washout (average of 80% signal loss per
ycle) after balloon deflation. Comparatively, high-
ose single-bolus administration resulted in a larger
nitial peak 18FDG-CPC myocardial signal fol-
owed by a slower, gradual decline. At 1 h, the
igh-concentration single-bolus group demon-
trated twice the PET signal of the low-
oncentration balloon occlusion group (p  0.08).
OMMENT. This study identifies the time course of
PC delivery in a large-animal MI model and
emonstrates in vivo noninvasive assessment of
arious cell-based myocardial regeneration thera-
ies. Although overall engraftment is low, a novel
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107igh-dose single-bolus delivery strategy without
alloon occlusion may be superior to a more labor-
ntensive occlusion technique that might induce
ownstream myocardial dysfunction.
ET/CT molecular imaging of gene expres-
ion. A minimally invasive clinical-type strategy
as used to locally administer reporter gene prod-
cts and then noninvasively evaluate their expres-
ion over time by hybrid PET/CT imaging (30).
enes (1010 plaque-forming units) were delivered
sing a percutaneous endomyocardial fluoroscopy-
uided delivery system equipped with a helical
eedle injector that allowed high-precision steering
f the catheter tip within the LV. Two days after
ocal gene delivery to swine hearts, 18F-labeled
-[4-fluoro-3-(hydroxymethyl)butyl] guanine
18F-FHBG), a reporter probe for imaging the
xpression of transfected genes, was intravenously
njected (9.37 mCi per animal). The PET/CT
mages revealed signal enhancement at the site of
nitial gene product injection in the anteroseptal
erritory. Compared with saline-injected controls,
ET signal was significantly greater in animals
eceiving myocardial reporter genes.
OMMENT. Noninvasive imaging of gene expres-
ion could play an important role in monitoring
Figure 6. Serial Bioluminescence Monitoring of ESC-EC Survival
(A) Representative images reveal signiﬁcant bioluminescence activit
 105 ESC-ECs. The robust signal intensity gradually diminishes ove
nescence signal from all animals. (C) Survival of donor cells over tim
centage signal activity from baseline). Reproduced, with permission
cell; other abbreviations as in Figure 3.ardiac gene therapy in clinical trials. iultimodality ImagingandTheranostics
he ability of a single imaging agent to provide
eadouts across multiple imaging modalities is in-
uitively attractive. In particular, derivatization of
maging agents with additional fluorescence report-
rs greatly augments the ability to rigorously vali-
ate the specificity of an imaging agent via fluores-
ence microscopy and flow cytometry. In addition,
ombining imaging platforms with complementary
trengths (e.g., CMR for noninvasive, high-
esolution detection, and PET or fluorescence for
igh-sensitivity detection) can augment the utility
f an imaging agent. An important consideration
or multimodality probes is the increased complex-
ty encountered during agent synthesis.
The continued evolution of molecular imaging
gents has also witnessed the development of ther-
nostic (combined therapeutic and diagnostic) im-
ging strategies. Theranostic agents offer the ability
o localize, track, and quantify a therapeutic molec-
lar target in a diseased tissue of interest. Such
nformation could be used to predict therapeutic
fficacy and/or modulate the delivered dose (e.g.,
njecting an additional dose of agent in tissues with
uboptimal uptake). These futuristic-sounding mo-
ecular approaches have gained increasing traction
I
tectable by day 2 in the post-MI mouse heart after injection of 5
e course of 8 weeks. (B) Temporal analysis of the ESC-EC biolumi-
om day 2 diminished markedly by week 8 (determined by per-
m Li et al. (29). ESC-EC  embryonic stem cell-derived endothelialin M
y de
r th
e fr
, fron recent years.
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108ultimodality PET-CMR-fluorescence imaging
f plaque macrophages. Nahrendorf et al. (32)
eveloped and validated a trimodality nanoparticle
TNP) for PET, CMR, and NIRF imaging of
esional macrophages. Based on the backbone of an
arlier NIR fluorescent MNP (33), TNP was deri-
atized with 64Cu (half-life: 12.7 h) to enable
oncomitant PET imaging. The PET-based detec-
ion of TNP was found to be 50-fold more sensitive
han CMR in vitro. Then TNP was injected into
poE/ mice (dose: 303 Ci, 1.5 mg Fe/kg).
fter 24 h, PET, CMR, and NIRF imaging were
erformed. In vivo TNP localized to aortic and
arotid plaques with a 260% to 392% signal increase
ver wild-type mice (Fig. 7). Flow cytometry and
uorescence microscopy confirmed macrophage
argeting of TNP. Compared with 18FDG-PET
maging in the same mouse, TNP enabled higher in
ivo plaque target-to-background ratios (TBRs).
OMMENT. By combining the sensitivity of PET
maging, the excellent soft tissue contrast of CMR,
nd the fluorescence capabilities of reflectance im-
ging, flow cytometry, and fluorescence microscopy,
he TNP agent is an important multimodal imaging
dvance in atherosclerosis molecular imaging.
imultaneous PET-CMR molecular imaging. A
ignificant technological advance, molecular imag-
Figure 7. Multimodality PET, CMR, and NIRF Imaging of Plaque
Strong 64Cu-TNP activity was observed in the (A) aortic root, (B) arc
sclerotic plaque burden in ApoE/ mice. (D to F) Comparatively, s
wild-type mice. Histology of respective vascular territories identiﬁed
controls (magniﬁcation: 400 for G and I, 200 for H and K; bar 
fused PET/CT data set demonstrates (L) focal 64Cu-TNP uptake (red
absent in matched wild-type control animals. Reproduced, with per
PET  positron emission tomography; TNP  trimodality nanoparting is now possible using combined 18FDG-PET tnd CMR. Judenhofer et al. (34) developed solid-
tate silicon photo sensors that were insensitive to
agnetic field variations and insertable directly into
MR scanners. Benchmark testing comparing the
ET insert alone or in combination with CMR
evealed little signal degradation or inhomogene-
ties. Excellent coregistration of molecular, anatom-
cal, and functional integrated CMR-PET images
as demonstrated in vivo in mice brain and colon
ancer studies.
OMMENT. Combining PET’s high-sensitivity
subpicomolar) detection of molecular targets with
MR’s anatomical, functional, and spectroscopic
apabilities is a major technological advance that
ill strongly influence cardiovascular, neurological,
ancer, and stem cell imaging. The simultaneous
cquisition of PET and CMR signals is particularly
mportant for functional imaging where physiolog-
cal states can change dynamically. Clinical PET-
MR scanners are under active development.
etection and treatment of plaque neovascular-
zation. Plaque angiogenesis may facilitate in-
raplaque hemorrhage, demarcate high-risk
laques, and represent an intriguing therapeutic
arget for atherosclerosis. Winter et al. (35) devel-
ped a theranostic antiangiogenic CMR-based
trategy for atherosclerosis. An angiogenesis-
rophages Using a 64Cu-Labeled TNP
nd (C) carotid artery on fused PET/CT images at sites of athero-
64Cu-TNP signal was identiﬁed in the same vascular beds of
h plaque content in ApoE/ mice but (I, K) not in wild-type
mm). Maximum intensity reconstruction of the 3-dimensional
the proximal thoracic aorta (blue) of ApoE/ mice that is (M)
ion, from Nahrendorf et al. (32). CT  computed tomography;
64Cu  copper Cu 64; other abbreviations as in Figures 1 and 2.Mac
h, a
cant
hig
0.4
) in
missargeted gadolinium-containing nanoparticle,
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109lphaV-beta3-MNP, was further derivatized by
umagillin, an antiangiogenic endothelial myco-
oxin. Atherosclerotic rabbits received a single dose
f fumagillin or control alphaV-beta3-MNP (1 ml/
g) and underwent T1-weighted turbo spin echo
MR before and 3 h after injection. Magnetic
esonance imaging was then performed weekly for 4
eeks after control alphaV-beta3-MNP injection.
n a second study, rabbits received 1 or 2 doses of
he fumagillin alphaV-beta3-MNP with or without
tatin therapy (atorvastatin 44 mg/kg), with serial
lphaV-beta3-MNP molecular CMR over 8 weeks
o assess angiogenesis. Neovessel MNP signal en-
ancement diminished by more than 50% at 1 week
fter fumagillin treatment and returned gradually to
aseline levels by 4 weeks. Signal enhancement
emained elevated in animals receiving control
lphaV-beta3-MNP without fumagillin. Remark-
bly, atorvastatin alone did not reduce angiogenesis,
owever atorvastatin combined with serial fumagil-
in dosing sustained an antiangiogenic effect in
theromata. In vivo findings were confirmed with
uorescent MNP studies as well as with histology.
OMMENT. This is an elegant approach employing
single agent to diagnose, monitor, and treat
ngiogenesis in atherosclerosis. Serial monitoring of
laque angiogenesis also enabled optimization of
he timing and dosing of antiangiogenic agents, as
ell as concomitant potentiators such as statins.
linical Investigations
ithin the extensive area of imaging agent devel-
pment, a major goal is to develop clinically useful
olecular imaging agents—specifically agents that
re nontoxic, sensitive, specific, efficient, and that
ossess favorable pharmacokinetic properties. Ad-
ances in clinical CVD molecular imaging over the
ast 3 years have already made a substantial impact
n atherosclerosis imaging of patients (e.g., 18FDG
or PET imaging, iron oxide MNP for CMR,
9mTc-annexin V for SPECT imaging). In the past
ear, clinical atherosclerosis molecular imaging
tudies provided new insights into the relationship
etween atherosclerosis and inflammation. In addi-
ion, new clinical molecular imaging approaches
ere also demonstrated for thrombosis and MI.
revalence of inﬂammation in carotid atherosclerosis
etermined by 18FDG PET/CT imaging. Uptake of
8FDG, a PET tracer that accumulates in metabol-
cally active cells, correlates with plaque macrophages.
o evaluate the prevalence of 18FDG-derived carotid
laque inflammation in asymptomatic individuals, pahara et al. (36) performed carotid 18FDG-PET
nd CT imaging on 100 consecutive subjects un-
ergoing screening carotid ultrasonography. Exclu-
ion criteria included active inflammatory syn-
romes (aortitis, vasculitis, acute coronary
yndromes) as well as the use of statins, previously
hown to reduce 18FDG signal in human carotid
laques (37). On ultrasound, 41% of patients har-
ored carotid atherosclerosis. However, only 30% of
hose with carotid atherosclerosis demonstrated el-
vated 18FDG carotid plaque signal indicating in-
ammation (standardized uptake value: 1.60)
Fig. 8). Enhanced 18FDG signal was noted in 10%
f patients without atherosclerosis, possibly identi-
ying subjects at greater future risk. Inflammation
erived from 18FDG correlated with elevated body
ass index, waist circumference, the use of antihy-
ertensive medications, and the number of athero-
clerotic plaques.
OMMENT. Roughly one-third of carotid plaques
rom asymptomatic patients are inflamed as deter-
ined by 18FDG-PET imaging. Prospective studies
re needed to determine if the presence of 18FDG-
efined plaque inflammation portends a greater risk of
troke or cardiovascular events.
eproducibility of atherosclerosis inﬂammation mea-
urements obtained by 18FDG-PET/CT imaging. The
hort-term reproducibility of 18FDG-PET imag-
ng of inflammatory lesions in carotid, iliac, and
emoral arteries was assessed in 19 high-risk
atients (38). Patients were imaged twice 14 days
part with combined vascular 18FDG-PET/CT.
xcellent interscan, interobserver, and intraob-
erver agreement was present for all vessel beds
interclass coefficients: 0.8). In addition to the
tandardized uptake value analysis, Rudd et al.
38) derived new TBR measures to quantify
8FDG plaque signal. The investigators sug-
ested tracking the mean TBR to assess systemic
therosclerosis therapies and using the maximum
laque TBR within a diseased segment to mon-
tor local therapies.
OMMENT. Clinical 18FDG-PET/CT imaging
f carotid and peripheral arterial plaques is re-
roducible over 14 days and strengthens this
pproach to monitor anti-inflammatory athero-
clerosis treatments. Ongoing 18FDG-PET
hase II studies may help determine which novel
harmacotherapies will be supported for costly
hase III outcome studies.
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110orrelation of carotid plaque inﬂammation with lumi-
al stenosis employing iron oxide nanoparticle-
nhanced CMR. Patients (n  71) with asymptom-
tic carotid stenosis 40% were injected with a
acrophage-targeted MNP for CMR, specifically
extran-coated USPIO, to evaluate the relationship
etween plaque inflammation and luminal stenosis
39). Spearman rank correlation coefficients dem-
nstrated no significant relationship between
NP-derived plaque inflammation and stenosis
rho  0.15, p  0.05).
OMMENT. This hypothesis-generating cross-
ectional study of asymptomatic subjects with
oderate carotid stenoses sheds light on the
ncongruity of anatomic indices and inflamma-
Figure 8. Clinical PET Imaging of Atherosclerosis Inﬂammation
Paired carotid 18FGD-PET and B-mode ultrasound images of human
derived evidence of plaque inﬂammation and patients without dete
arrows  18FDG-PET signal uptake. Yellow arrows  carotid athero
CA-US  carotid atherosclerosis ultrasound; 18FGD  ﬂuorodeoxyge
of Fibrin-Rich Thrombi
e molecular imaging of a descending aortic thrombus with a
P-2104R) in an 82-year-old female patient. The thrombus is visual-
st (arrow) on the inversion recovery black-blood gradient-echo
Reconstructed images from a corresponding contrast-enhanced
otic ﬁlling defect and note a small region of calciﬁcation (arrow-
th permission, from Spuentrup et al. (40). Abbreviations as in Fig-iion. Elevated plaque inflammation is present
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linical outcomes studies are needed to deter-
ine the risk of moderate and severe asymptom-
tic lesions based on the underlying degree of
laque inflammation.
maging ﬁbrin in cardiovascular thrombi using CMR.
puentrup et al. (40) performed a multicenter
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cal molecular CMR agent for thrombosis that
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104R for acute arterial thrombosis syndromes,
brin CMR could offer a noninvasive option to
ransesophageal echocardiography for left atrial
hrombi. In addition, detection of subclinical
hrombi on carotid atheroma could identify high-
isk patients.
etection of post-infarction angiogenesis by SPECT/CT
ients having atherosclerotic disease (A) with or (B) without 18FDG-
le atherosclerosis (C) with or (D) without inﬂammation. White
rotic plaque. Reproduced, with permission, from Tahara et al. (36).
e F 18; other abbreviations as in Figure 7.pat
ctab
scleFigure 9. Clinical CMR
(A) Magnetic resonanc
ﬁbrin-speciﬁc probe (E
ized as positive contra
imaging sequence. (B)
CT conﬁrm the thromb
head). Reproduced, wimaging. Positron emission tomography imaging
w
1
a
l
e
s
d
t
o
d
d
i
1
u
s
nd
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 , 2 0 0 9
J A N U A R Y 2 0 0 9 : 9 7 – 1 1 3
Osborn and Jaffer
Year in Molecular Imaging
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8F-Galakto-RGD was used to evaluate post-MI
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Figure 10. Clinical PET Imaging of Infarct Angiogenesis
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112OMMENT. This case report demonstrates the po-
ential to image post-MI angiogenesis using non-
nvasive PET imaging. Clinical studies are needed
o determine whether angiogenesis imaging can
redict long-term LV function after MI.
onclusions
olecular imaging of CVD has witnessed an exciting
ear. An array of reporter imaging strategies now
rovides the ability to sense fundamental biological
rocesses across a range of CVD states and imaging
latforms. In the clinical arena, rapid growth is antic-targeted microparticles of iron oxide.
specific epitopes.
117:3206–15.ate new pharmaceuticals in phase II clinical trials (in
articular, imaging of drug-induced effects on plaque
nflammation). The next phase of clinical molecular
maging studies will aim to provide longitudinal bio-
ogical information about the evolution of CVD in
atients and will undoubtedly offer new opportunities
o identify patients at risk for rapid disease progression
nd adverse outcomes.
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